Samer Alsaid։ Older Patients With Atrial Fibrillation Benefit From FXI Inhibition
Samer Alsaid, Cardiologist and Vascular Medicine Specialist, shared a post on LinkedIn about a recent article he co-authored with his colleagues, adding:
՛՛Bleeding risk rises steadily with age in patients with atrial fibrillation — underscoring the need for safer anticoagulant options in older individuals.
In our prespecified analysis of the phase 2b AZALEA-TIMI 71 trial, now published in JAMA Cardiology, the FXI inhibitor abelacimab consistently reduced bleeding compared with rivaroxaban across age groups, with the potential for greater absolute reductions in older patients.
FXI inhibition may become a particularly attractive option for older patients with AF, but phase 3 trial results are needed to define its efficacy and overall benefit-risk balance.
Grateful to an outstanding group of collaborators, mentors, and the AZALEA-TIMI 71 investigators who made this work possible․՛՛
Title: Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation
Authors: Samer Al Said, Siddharth M. Patel, Robert P. Giugliano, David A. Morrow, Erica L. Goodrich, Sabina A. Murphy, Bruce Hug, Sanobar Parkar, Shih-Ann Chen, Shaun G. Goodman, Boyoung Joung, Robert G. Kiss, Wojciech Wojakowski, Jeffrey I. Weitz, Dan Bloomfield, Marc S. Sabatine, Christian T. Ruff
Read the Full Article on JAMA Cardiology․
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia
-
Aug 23, 2026, 16:03Balaji Balagani: Major Causes of Sudden Cardiac Death in Children
-
Aug 23, 2026, 16:02Bartosz Hudzik: What’s Hot at ESC Congress 2026